Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
BACKGROUND: Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithr...
| Autor principal: | |
|---|---|
| Formato: | Published Article |
| Publicado: |
2020-04-23
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.1101/2020.04.16.20065920 https://hdl.handle.net/20.500.12663/1845 |
| id |
PAO-20.500.12663-1845 |
|---|---|
| record_format |
dspace |
| spelling |
Magagnoli, Joseph et al. 2020-06-29T17:56:15Z 2020-06-29T17:56:15Z 2020-04-23 https://doi.org/10.1101/2020.04.16.20065920 https://hdl.handle.net/20.500.12663/1845 BACKGROUND: Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithromycin, is being widely used in Covid-19 therapy based on anecdotal and limited observational evidence. METHODS: We performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020. Patients were categorized based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) as treatments in addition to standard supportive management for Covid-19. The two primary outcomes were death and the need for mechanical ventilation. We determined the association between treatment and the primary outcomes using competing risk hazard regression adjusting for clinical characteristics via propensity scores. Discharge and death were taken into account as competing risks and subdistribution hazard ratios are presented. RESULTS: A total of 368 patients were evaluated (HC, n=97; HC+AZ, n=113; no HC, n=158). Rates of death in the HC, HC+AZ, and no HC groups were 27.8%, 22.1%, 11.4%, respectively. Rates of ventilation in the HC, HC+AZ, and no HC groups were 13.3%, 6.9%, 14.1%, respectively. Compared to the no HC group, the risk of death from any cause was higher in the HC group (adjusted hazard ratio, 2.61; 95% CI, 1.10 to 6.17; P=0.03) but not in the HC+AZ group (adjusted hazard ratio, 1.14; 95% CI, 0.56 to 2.32; P=0.72). The risk of ventilation was similar in the HC group (adjusted hazard ratio, 1.43; 95% CI, 0.53 to 3.79; P=0.48) and in the HC+AZ group (adjusted hazard ratio, 0.43; 95% CI, 0.16 to 1.12; P=0.09), compared to the no HC group. CONCLUSIONS: In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19. An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone. These findings highlight the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs. English COVID-19 Coronavirus Hydroxychloroquine United States Veterans Hospitalization Azithromycin Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 medRxiv Global (WHO/OMS) Candidate therapeutics RD Published Article Save Lives / Salvar Vidas |
| elec_str_mv |
Organización Panamericana de la Salud |
| collection |
Organización Panamericana de la Salud |
| title |
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 |
| spellingShingle |
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Magagnoli, Joseph et al. COVID-19 Coronavirus Hydroxychloroquine United States Veterans Hospitalization Azithromycin |
| title_short |
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 |
| title_full |
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 |
| title_fullStr |
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 |
| title_full_unstemmed |
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 |
| title_sort |
outcomes of hydroxychloroquine usage in united states veterans hospitalized with covid-19 |
| author |
Magagnoli, Joseph et al. |
| author_facet |
Magagnoli, Joseph et al. |
| topic |
COVID-19 Coronavirus Hydroxychloroquine United States Veterans Hospitalization Azithromycin |
| topic_facet |
COVID-19 Coronavirus Hydroxychloroquine United States Veterans Hospitalization Azithromycin |
| publishDate |
2020-04-23 |
| format |
Published Article |
| description |
BACKGROUND: Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithromycin, is being widely used in Covid-19 therapy based on anecdotal and limited observational evidence. METHODS: We performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020. Patients were categorized based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) as treatments in addition to standard supportive management for Covid-19. The two primary outcomes were death and the need for mechanical ventilation. We determined the association between treatment and the primary outcomes using competing risk hazard regression adjusting for clinical characteristics via propensity scores. Discharge and death were taken into account as competing risks and subdistribution hazard ratios are presented. RESULTS: A total of 368 patients were evaluated (HC, n=97; HC+AZ, n=113; no HC, n=158). Rates of death in the HC, HC+AZ, and no HC groups were 27.8%, 22.1%, 11.4%, respectively. Rates of ventilation in the HC, HC+AZ, and no HC groups were 13.3%, 6.9%, 14.1%, respectively. Compared to the no HC group, the risk of death from any cause was higher in the HC group (adjusted hazard ratio, 2.61; 95% CI, 1.10 to 6.17; P=0.03) but not in the HC+AZ group (adjusted hazard ratio, 1.14; 95% CI, 0.56 to 2.32; P=0.72). The risk of ventilation was similar in the HC group (adjusted hazard ratio, 1.43; 95% CI, 0.53 to 3.79; P=0.48) and in the HC+AZ group (adjusted hazard ratio, 0.43; 95% CI, 0.16 to 1.12; P=0.09), compared to the no HC group. CONCLUSIONS: In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19. An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone. These findings highlight the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs.
|
| url |
https://doi.org/10.1101/2020.04.16.20065920 https://hdl.handle.net/20.500.12663/1845 |
| work_keys_str_mv |
AT magagnolijosephetal outcomesofhydroxychloroquineusageinunitedstatesveteranshospitalizedwithcovid19 |
| _version_ |
1737882847451021312 |